Pharma Journalist 9027 posts 0 comments

Alexion’s Ultomiris (ravulizumab) has been recommended for marketing authorisation in the European Union (EU) for expanded use to include children and adolescents with paroxysmal…
Read More...

Akston Biosciences Corporation, a developer of new classes of biologic therapeutics, announced a commercial agreement with Seppic S.A., a supplier of specialty healthcare ingredients,…
Read More...

Results from the Canadian Immunization Research Network (CIRN) with support from Public Health Agency of Canada and the Canadian Institutes of Health Research, published as a pre-print,…
Read More...

ImaginAb Inc, a market leading global biotechnology company, focused on developing next generation immuno oncology imaging agents and therapeutic radiopharmaceuticals (RPT), announced…
Read More...

Acorda Therapeutics, Inc. announced that it has entered into distribution and supply agreements with Esteve Pharmaceuticals S.A (ESTEVE) to commercialize INBRIJA 33 mg (levodopa…
Read More...

Arvinas, Inc. and Pfizer Inc. announced a global collaboration to develop and commercialize ARV-471, an investigational oral PROTAC (PROteolysis TArgeting Chimera) estrogen receptor…
Read More...

Merck, known as MSD outside the United States and Canada, and Eisai Inc. announced that the U.S. Food and Drug Administration (FDA) has approved the combination of KEYTRUDA, Merck’s…
Read More...

LEXEO Therapeutics, a fully integrated clinical-stage gene therapy company advancing disease-modifying treatments for genetic conditions, announced that it has acquired Stelios…
Read More...

The World Clinical Biomarkers & CDx Summit returns for the 11th year! Once again uniting the Biomarker and Diagnostic community from across Biopharma, Academia and Diagnostic…
Read More...

AstraZeneca completed the acquisition of Alexion Pharmaceuticals, Inc. (Alexion). The closing of the acquisition marks the Company’s entry into medicines for rare diseases and the…
Read More...